Navigation Links
Scripps Research scientist receives $1 million research grant from Novo Nordisk
Date:11/8/2011

JUPITER, FL, November 8, 2011 Andrew Butler, an associate professor in The Scripps Research Institute's Department of Metabolism and Aging, has been awarded one million dollars in funding over the next two years to further his research into a novel protein with the potential to improve the understanding and future treatment of diabetes.

The award is notable in that it comes not from the US National Institutes of Health but from Novo Nordisk, an international healthcare company based in Denmark recognized as a world-leader in diabetes treatment.

The Novo Nordisk Diabetes Innovation Award Program was launched in 2011 to help scientists substantiate early research efforts that could result in new treatment options for diabetes and obesity.

Butler's two-year research project, entitled the "Investigation of a Novel Peptide Hormone in Diabetes Treatment," was selected from more than 80 submitted proposals from US and Canadian research institutions.

The research involves a peptide hormone secreted by the liver called adropin. Animal models have shown that peptide hormones play an important role in regulating glucose levels and fatty acid metabolism and that irregular function of these hormones can have a direct effect on an individual's risk of developing obesity and/or diabetes.

"We were studying animal models of insulin resistance as precursor to type 2 diabetes, when we came across adropin," Butler said. "We found it provocative that this particular peptide hormone was distributed in the brain, liver, and pancreasthree tissues that are of great interest to those of us in the diabetes research field."

Butler noted that adropin seems to play a role in maintaining normal insulin sensitivitywhereby only a relatively small amount of insulin is needed to maintain regular blood glucose levels. In type 2 diabetes, insulin sensitivity is often blunted, which means that the normal amounts of insulin produced by the body are no longer as effective in lowering blood glucose levels.

"What has not been established are the mechanisms and sites of action that effect glucose homeostasis [equilibrium]," he said. "So that's what we're going to spend the next two years finding out with the help of this research grant from Novo Nordisk."

The research will also explore adropin's potential role as a protein-based therapy for treating type 2 diabetes, a chronic disease that affects over 300 million people worldwide, according to the World Health Organization. "Clearly, there is an urgent need to identify new and more effective drugs for treating diabetes," Butler said. "Studying how adropin works in this regard could eventually contribute to this effort."


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Florida scientist awarded $2.2 million grant to study hepatitis C
2. Scripps research scientist wins $3.6 million NIH Method to Extend Research in Time award to study alcoholism in Native Americans
3. Scripps Health and Sanford-Burnham to collaborate to advance new cancer treatments
4. Scripps Research scientists reveal how white blood cell promotes growth and spread of cancer
5. Scripps Research scientists define cellular pathway essential to removing damaged mitochondria
6. Scripps Translational Science Institute joins Jackson Laboratory tumor consortium
7. Scripps Research scientists show how shifts in temperature prime immune response
8. CIRM awards Scripps Research Institute scientists $3.5 million
9. Scripps Research wins more than $2 million to study prostate cancer
10. New lupus drug results from Scripps Research technology
11. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research scientist receives $1 million research grant from Novo Nordisk
(Date:1/23/2017)... , ... January 23, 2017 , ... ... high-quality general gynecological care and gynecological services for women of all ... care for a wide variety of reproductive services from routine health screenings to ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events that happen ... creation of published author, Charlotte Hotte, a North Carolina native, a mother of two, ... book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, along with ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: ... from an early age. “Life Under Blankets” is the creation of published author, Kimberly ... Circle Campus in Chicago. She went on to pursue a master’s degree in education ...
(Date:1/23/2017)... ... ... Day is a time when many people celebrate romance and love by giving cards, candy, ... the ideal present, Atlanta-based Perimeter Plastic Surgery is offering a Valentine’s Day special: ... and get $50 free. , “A lot of people just buy the more predictable ...
(Date:1/22/2017)... ... 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a unique ... buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle ... in all of its creations to help create a more traditional and natural approach ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , January 23, 2017 Longer life expectancy and ... the global market for medical device technologies. BCC Research reveals ... Asia-Pacific region, should see strong growth due to ... disposable incomes. Continue Reading ... ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
(Date:1/23/2017)... Spain , January 23, 2017 /PRNewswire/ ... biopharmaceutical company focused on treatments for calcification disorders, ... enrolled in the Phase IIb "CaLIPSO Study" clinical ... of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients ... in the last stage of chronic kidney disease, ...
Breaking Medicine Technology: